Table 1.
Demographics and clinical characteristics of patients included in this study.
| Figure 1 | Figure 2 | Figure 3 | Figure 4 | Figure 5 | All | |
|---|---|---|---|---|---|---|
| Samples | ||||||
| Liver | 4 | 19 | 8 | – | – | 27* |
| Matched PBMC | 4 | 19 | 0 | – | – | 19* |
| Hepatocyte organoids | – | – | – | 7 | 7** | |
| Demographics | ||||||
| Sex (f/m) | 2/2 | 7/12 | 4/4 | – | 4/3 | 15/19 |
| Median age in years (Range) | 57 (43-68) | 57 (43-68) | 56 (45-65) | – | 57 (50-75) | 57 (43-75) |
| Primary liver disease (LTX) | 17 | |||||
| ALD | 0 | 4 | 0 | – | – | 4 |
| HCV | 0 | 2‡ | 0 | – | – | 2‡ |
| HCC | 0 | 5† | 4† | – | – | 9† |
| PLD | 0 | 0 | 1 | – | – | 1 |
| PSC | 0 | 0 | 1 | – | – | 1 |
| Primary liver disease (AKB) | 17* | |||||
| Colorectal carcinoma | 3 | 7 | 2 | – | 5 | 14* |
| Inflammatory adenoma | 1 | 1 | 0 | – | 0 | 1* |
| Cholangiocellular carcinoma | 0 | 0 | 0 | – | 1 | 1 |
| Hemangioma | 0 | 0 | 0 | - | 1 | 1 |
| CMV serological status | ||||||
| positive/negative/unknown | 4/0/0 | 14/5/0 | 6/1/1 | – | 0/0/7 | 20/6/8 |
*Samples of 4 patients with eiter colorectal carcinoma metastasis or liver adenoma were used in two experiments.
**Hepatocyte organoids from 7 individuals were used for 15 experiments in figure 5.
†HCC was based on: 4x HCV, 1x HBV with HDV, 1x CC, 1x NASH and 2x ALD.
‡One patient suffered from HBV and HCV simultaneously.
AKB, Asklepios Hospital Barmbek liver resection cohort; ALD, alcoholic liver disease; CC, cryptogenic cirrhosis; CMV, cytomegalovirus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; LTX liver transplantation cohort; NASH, non-alcoholic steatohepatitis; PBMC, peripheral blood mononuclear cells; PLD, polycystic liver disease; PSC, primary sclerosing cholangitis.